{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-017637","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.843080+00:00","generated_at":"2026-05-15T02:36:43.928203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B","bullets":["Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.","TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.","2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).","Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.","Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-017637","json":"https://secwatch.observer/filing/0001140361-26-017637.json","markdown":"https://secwatch.observer/filing/0001140361-26-017637.md","text":"https://secwatch.observer/filing/0001140361-26-017637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/0001140361-26-017637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:36:43.928203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e412cd1772888218647e8c55061cb8ade45221d5","claim":"IONIS PHARMACEUTICALS INC reported first quarter 2026 results: revenue $246 million. Guidance raised.","evidence_excerpt":"First Quarter 2026 Summary Financial Results (1): Three months ended March 31, 2026 2025 (amounts in millions) Total revenue $ 246 $ 132 Operating expenses $ 364 $ 278 Operating expenses on a non-GAAP basis $ 321 $ 249 Loss from operations $ (118 ) $ (146 ) Loss from operations on a non-GAAP basis $ (75 ) $ (117 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/0001140361-26-017637-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$246 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}